尤瑞克林对急性脑梗死患者的疗效及安全性观察

目的观察尤瑞克林治疗急性脑梗死的疗效及安全性。方法 120例急性脑梗死患者随机分成治疗组(n=60)和对照组(n=60),在对症治疗基础上,治疗组及对照组分别采用尤瑞克林和疏血通治疗,评定治疗前后神经功能缺损程度评分(NIHSS)、残障评分(mRS),并随访3个月的残障评分(mRS)。结果尤瑞克林治疗后脑梗死患者的NIHSS和mRS较治疗前均显著降低(P<0.05),且治疗后与对照组比较有统计学差异(P<0.05)。治疗组疗效明显优于对照组(P<0.05),血压无明显波动(P>0.05)。结论尤瑞克林治疗急性脑梗死安全有效,值得临床推广使用。

Objective To investigate the efficacy and safety of Human Urinary Kallidinogenase（HUK） Injection in treatment of patients with acute cerebral infarction. Methods Atotal 120 in patients with acute cerebralinfarction were randomly divided into treatment group （n=60）and control group（n=60）. Control group and treatment group received Shuxuetong and HUK Treatment before, and after treatment, to assess the extent of neurological deficits score （NIHSS）, disability score （mRS）, and followed up 3 months of the disability score （mRS）. Results After treatment, Patients with cerebral infarction NIHSS score and mRS score were significantly lower than pre-treatment （P〈0.05）,and the difference was statistically significant compared with the control group （P〈0.05）. Treatment group significantly better than the control group（P〈0.05）,no significant fluctuations in blood pressure （P〉0.05）.Conclusion HUK is an effective and safe treatment against acute cerebral infarction,few and mild adverse reactions,it is worth for clinical use.